Chiral distinction between hydroxychloroquine enantiomers in binding to angiotensin-converting enzyme 2, the forward receptor of SARS-CoV-2

Soon after the outset of the Coronavirus Disease 2019 (COVID-19) pandemic (March-April 2020), formulations of the old antimalarial racemic drug hydroxychloroquine (HCQ) sulfate were authorized by the U.S. Food and Drug Administration (FDA) for emergency treatment of hospitalized patients with COVID-...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of pharmaceutical and biomedical analysis 2024-01, Vol.237, p.115770-115770, Article 115770
Hauptverfasser:	Aiello, Federica, Balzano, Federica, Uccello Barretta, Gloria, D’Acquarica, Ilaria, Mazzoccanti, Giulia, Agranat, Israel
Format:	Artikel
Sprache:	eng
Schlagworte:	Chiral distinction Chiral switch Drug repurposing Drug/protein interaction NMR spectroscopy Proton relaxation rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!